Trial Profile
Evaluation of Satisfaction in Patients Receiving PegIntron (peginterferon-alfa-2b) Pen / Rebetol (ribavirin) for Hepatitis C
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 05 Jun 2009 Actual number of patients (185) added as reported by ClinicalTrials.gov.
- 21 Jul 2008 New trial record.